Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $44.12 million. The enterprise value is $41.30 million.
Important Dates
The last earnings date was Friday, November 13, 2026, before market open.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 62.02 million shares outstanding. The number of shares has increased by 87.91% in one year.
| Current Share Class | 62.02M |
| Shares Outstanding | 62.02M |
| Shares Change (YoY) | +87.91% |
| Shares Change (QoQ) | +13.63% |
| Owned by Insiders (%) | 15.69% |
| Owned by Institutions (%) | 13.48% |
| Float | 52.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88
| Current Ratio | 0.88 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -455.86% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 7,763.30% |
| Weighted Average Cost of Capital (WACC) | 11.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.39M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.96% in the last 52 weeks. The beta is 1.35, so Annovis Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -78.96% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 38.57 |
| Average Volume (20 Days) | 3,662,663 |
Short Selling Information
The latest short interest is 5.36 million, so 8.64% of the outstanding shares have been sold short.
| Short Interest | 5.36M |
| Short Previous Month | 5.90M |
| Short % of Shares Out | 8.64% |
| Short % of Float | 10.24% |
| Short Ratio (days to cover) | 7.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.07M |
| Pretax Income | -51.72M |
| Net Income | -51.72M |
| EBITDA | n/a |
| EBIT | -59.07M |
| Earnings Per Share (EPS) | -$1.55 |
Full Income Statement Balance Sheet
The company has $2.82 million in cash and no debt, with a net cash position of $2.82 million or $0.05 per share.
| Cash & Cash Equivalents | 2.82M |
| Total Debt | n/a |
| Net Cash | 2.82M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | -13.23M |
| Book Value Per Share | -0.31 |
| Working Capital | -760,825 |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -43.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -55.89M |
| FCF Per Share | -$0.90 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -87.91% |
| Shareholder Yield | n/a |
| Earnings Yield | -217.49% |
| FCF Yield | -126.69% |
Analyst Forecast
The average price target for Annovis Bio is $9.50, which is 1,235.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 1,235.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |